249 related articles for article (PubMed ID: 21330902)
1. Peripheral neuropathy in HIV: prevalence and risk factors.
Evans SR; Ellis RJ; Chen H; Yeh TM; Lee AJ; Schifitto G; Wu K; Bosch RJ; McArthur JC; Simpson DM; Clifford DB
AIDS; 2011 Apr; 25(7):919-28. PubMed ID: 21330902
[TBL] [Abstract][Full Text] [Related]
2. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.
Chen H; Clifford DB; Deng L; Wu K; Lee AJ; Bosch RJ; Riddler SA; Ellis RJ; Evans SR
J Neurovirol; 2013 Dec; 19(6):557-64. PubMed ID: 24297499
[TBL] [Abstract][Full Text] [Related]
3. Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.
Lee AJ; Bosch RJ; Evans SR; Wu K; Harrison T; Grant P; Clifford DB
J Neurovirol; 2015 Apr; 21(2):210-8. PubMed ID: 25678143
[TBL] [Abstract][Full Text] [Related]
4. Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Arenas-Pinto A; Thompson J; Musoro G; Musana H; Lugemwa A; Kambugu A; Mweemba A; Atwongyeire D; Thomason MJ; Walker AS; Paton NI;
J Neurovirol; 2016 Feb; 22(1):104-13. PubMed ID: 26323809
[TBL] [Abstract][Full Text] [Related]
5. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.
Lichtenstein KA; Armon C; Baron A; Moorman AC; Wood KC; Holmberg SD;
Clin Infect Dis; 2005 Jan; 40(1):148-57. PubMed ID: 15614705
[TBL] [Abstract][Full Text] [Related]
6. Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
Yeh TM; Evans SR; Gulick RM; Clifford DB
HIV Clin Trials; 2010; 11(1):51-8. PubMed ID: 20400411
[TBL] [Abstract][Full Text] [Related]
7. HIV peripheral neuropathy progression: protection with glucose-lowering drugs?
Evans SR; Lee AJ; Ellis RJ; Chen H; Wu K; Bosch RJ; Clifford DB
J Neurovirol; 2012 Oct; 18(5):428-33. PubMed ID: 22806348
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Kiwuwa-Muyingo S; Kikaire B; Mambule I; Musana H; Musoro G; Gilks CF; Levin JB; Walker AS
AIDS; 2014 Nov; 28(17):2579-88. PubMed ID: 25574960
[TBL] [Abstract][Full Text] [Related]
9. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.
Ellis RJ; Rosario D; Clifford DB; McArthur JC; Simpson D; Alexander T; Gelman BB; Vaida F; Collier A; Marra CM; Ances B; Atkinson JH; Dworkin RH; Morgello S; Grant I;
Arch Neurol; 2010 May; 67(5):552-8. PubMed ID: 20457954
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.
Banerjee S; McCutchan JA; Ances BM; Deutsch R; Riggs PK; Way L; Ellis RJ
AIDS; 2011 Jan; 25(2):F1-6. PubMed ID: 21150557
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy in patients with human immunodeficiency viral infection at a tertiary hospital in Ghana.
Puplampu P; Ganu V; Kenu E; Kudzi W; Adjei P; Grize L; Käser M
J Neurovirol; 2019 Aug; 25(4):464-474. PubMed ID: 31028691
[TBL] [Abstract][Full Text] [Related]
12. HIV neuropathy in pre-HAART patients and it's correlation with risk factors in Central India.
Dubey TN; Raghuvanshi SS; Sharma H; Saxena R
Neurol India; 2013; 61(5):478-80. PubMed ID: 24262448
[TBL] [Abstract][Full Text] [Related]
13. Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.
Van der Watt JJ; Wilkinson KA; Wilkinson RJ; Heckmann JM
BMC Infect Dis; 2014 Feb; 14():71. PubMed ID: 24512313
[TBL] [Abstract][Full Text] [Related]
14. Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: A 6-month follow-up study.
Pillay P; Wadley AL; Cherry CL; Karstaedt AS; Kamerman PR
J Peripher Nerv Syst; 2019 Dec; 24(4):304-313. PubMed ID: 31587421
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
Hulgan T; Haas DW; Haines JL; Ritchie MD; Robbins GK; Shafer RW; Clifford DB; Kallianpur AR; Summar M; Canter JA
AIDS; 2005 Sep; 19(13):1341-9. PubMed ID: 16103764
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.
Mehta SA; Ahmed A; Kariuki BW; Said S; Omasete F; Mendillo M; Laverty M; Holzman R; Valentine F; Sivapalasingam S
Am J Trop Med Hyg; 2010 Sep; 83(3):565-70. PubMed ID: 20810821
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda.
Tumusiime DK; Venter F; Musenge E; Stewart A
BMC Public Health; 2014 Dec; 14():1306. PubMed ID: 25526665
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
19. Age and height predict neuropathy risk in patients with HIV prescribed stavudine.
Cherry CL; Affandi JS; Imran D; Yunihastuti E; Smyth K; Vanar S; Kamarulzaman A; Price P
Neurology; 2009 Jul; 73(4):315-20. PubMed ID: 19636052
[TBL] [Abstract][Full Text] [Related]
20. Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa.
Peters RP; Van Ramshorst MS; Struthers HE; McIntyre JA
Eur J Pediatr; 2014 Sep; 173(9):1245-8. PubMed ID: 24691679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
